Vadimezan

Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.

Product Specifications

CAS Number

[117570-53-3]

Product Name Alternative

DMXAA; ASA-404

UNSPSC

12352005

Hazard Statement

H302, H400

Target

IFNAR; Influenza Virus; STING

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/DMXAA.html

Purity

99.93

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)CC1=CC=CC(C2=O)=C1OC3=C2C=CC(C)=C3C

Molecular Formula

C17H14O4

Molecular Weight

282.29

Precautions

H302, H400

References & Citations

[1]Downey CM, et al. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014 Jun 18;9 (6) :e99988.|[2]Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89 (3) :351-7.